Highlights

  • Integrated Research (ASX:IRI) is repositioning its software Business towards subscription-based Revenue and digital platforms.
  • FY26 performance reflected weaker enterprise demand, delayed contracts and revenue pressure.
  • The company maintains a strong cash position to support its transformation strategy.
  • Future performance will depend on contract renewals, new product adoption and a recovery in revenue momentum.

Integrated Research (ASX:IRI) is undergoing a significant transition as the long-standing software provider works to rebuild growth momentum following a challenging FY26 period. The company remains focused on its core capability of monitoring and managing critical IT infrastructure while shifting towards subscription-based offerings and newer technology platforms.

As on 4 September 2026, Integrated Research (ASX:IRI) was trading at AUD 0.29, down 3.33% on the day. The movement comes as investors continue assessing the company’s turnaround strategy, financial position and ability to stabilise revenue performance.

Business Reset

Integrated Research has spent decades developing software solutions that help organisations monitor the performance and reliability of critical systems across sectors including payments, communications and enterprise technology.

However, the company faced a challenging FY26 period, with softer contract renewals, delayed customer decisions and cautious enterprise technology spending affecting revenue performance.

The company is now focused on strengthening Recurring Revenue streams through subscription-based solutions and expanding its newer platforms, including Elevate and Iris AI.

This transition represents an effort to create a more predictable business model while adapting to changing technology purchasing trends.

Financial Performance

A key update came on 24 July 2026, when Integrated Research highlighted a significant reduction in FY26 revenue expectations.

The company guided to statutory revenue of approximately $56 million to $58 million, compared with $68.3 million previously. Pro-forma revenue was expected to be between $64 million and $66 million, compared with $74.3 million in the prior period.

The company also indicated an expected EBITDA loss of approximately $2 million to $4 million, compared with previous profitability.

Management attributed the weaker performance to lower-than-expected contract renewals, reduced momentum from first-half new business activity and delays in customer decisions extending into FY27.

Despite the Earnings pressure, Integrated Research maintained a strong balance sheet, with cash increasing to $51.7 million, providing financial flexibility as the company executes its transformation strategy.

Strategic Position

Integrated Research operates in the performance monitoring and observability software market, providing tools for businesses where system reliability and uptime are critical.

The company’s established customer relationships provide a foundation for future growth, but enterprise software sales cycles can be lengthy and revenue can fluctuate depending on the timing of large contracts.

The company’s strategic focus is increasingly centred on recurring subscription revenue, which could provide greater earnings visibility over time.

The development of platforms such as Elevate and Iris AI forms part of the company’s broader effort to align its offering with evolving enterprise technology requirements.

Investor Considerations

Integrated Research presents a turnaround-focused Investment case, with the company’s strong cash position providing support while it works through operational challenges.

The key question for investors is whether the FY26 revenue decline represents a temporary disruption or a longer-term structural challenge.

The company’s transition towards subscription-based revenue could improve business stability if successfully executed, but achieving this shift requires customer adoption, product competitiveness and effective sales execution.

The Balance Sheet provides flexibility, although investors will continue monitoring how effectively management converts available resources into renewed growth.

Key areas to watch include renewal rates, new contract wins, revenue recovery and progress towards returning to positive earnings.

Upcoming Catalysts

Future performance will depend on several operational milestones, including whether delayed contracts convert during FY27 and whether the company can accelerate adoption of its newer software platforms.

Investors will also monitor progress in recurring revenue growth, cost management initiatives and any improvement in enterprise technology spending conditions.

A return towards positive EBITDA and evidence of stabilising revenue would represent important indicators that the company’s transformation strategy is gaining traction.

The company’s cash position may also provide strategic flexibility as management evaluates opportunities to strengthen its software portfolio.

Conclusion

Integrated Research (ASX:IRI) is navigating a critical phase as it attempts to reshape its business model and restore investor confidence. While FY26 highlighted challenges around enterprise Demand and revenue timing, the company retains valuable technology capabilities and a strong financial position.

The success of the turnaround will depend on execution, particularly the ability to grow subscription revenue, convert customer opportunities and rebuild earnings momentum. For now, the company’s progress towards stabilising operations remains the key focus for investors.